Eravacycline (ERV) was used in 35 patients for various infections. The most common pathogen was Klebsiella pneumoniae, and 30-day survival was 74%. Absence of 30-day recurrence and resolution of signs and symptoms of infection were 91% and 57%, respectively. ERV was well-tolerated, with adverse events leading to drug discontinuation in one patient.

Disclaimer In an effort to expedite the publication of articles related to the COVID-19 pandemic, AJHP is posting these manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.

As of December 2020, there were over 450,000 confirmed coronavirus disease 2019 cases in New York City (NYC) with approximately 25,000 deaths. Previous literature identified advanced age, higher severity of illness, elevated inflammatory biomarkers, acute organ dysfunction, comorbidities, and presentation from long-term care facility as risk factors for mortality in patients from Wuhan, China, and the United States. Additional studies conducted in NYC are warranted to confirm these findings.The objective of this study was to assess the risk factors for in-hospital mortality in patients with confirmed COVID-19 infections. This was a retrospective case-control study at The Brooklyn Hospital Center, a 464-bed community teaching hospital. Adult patients with a confirmed COVID-19 infection and who received at least 24 h of COVID-19 therapy were included. Univariate and multivariate logistic regression analyses were conducted to identify the risk factors for in-hospital mortality. Twohundred and eighty four patients were included, of whom 95 (33.5%) were nonsurvivors and 189 (66.5%) patients were survivors. Multivariate analysis showed higher in-hospital mortality with advanced age (odds ratio [OR] 6.476; 95% confidence interval [CI], 1.827-22.953), presentation from long-term care facility (OR 4.259; 95% CI 1.481-12.250), elevated total bilirubin (OR 4.947; 95% CI 1.048-23.350), vasopressor initiation (OR 36.262; 95% CI 5.319-247.216), and development of renal failure (OR 36.261; 95% CI 2.667-493.046). Risk factors associated with mortality for patients with COVID-19 in a community teaching hospital included advanced age, vasopressor initiation, development of renal failure, elevated total bilirubin, and presentation from long-term care facility.

Objective To compare clinical characteristics and outcomes of bloodstream infections (BSI) caused by Candida auris and other Candida spp. Methods Multicenter, retrospective, case-control study at three hospitals in Brooklyn, New York between 2016 and 2020. Patients ≥18 years of age with a positive blood culture for any Candida spp. treated empirically with an echinocandin were included in the analysis. The primary outcome was 30-day mortality. Secondary outcomes were 14-day clinical failure, 90-day mortality, 60-day microbiologic recurrence, and in-hospital mortality. Results 196 patients were included in the final analysis including 83 cases of candidemia caused by C. auris. After inverse propensity adjustment, C. auris BSI was not associated with increased odds of 30-day mortality (aOR 1.014 (0.563-1.828), p = 0.963) or 90-day mortality (aOR 0.863 (0.478-1.558), p = 0.625). A higher risk for microbiologic recurrence within 60 days of completion of antifungal therapy was observed in C. auris patients (aOR 4.461 (1.033-19.263), p = 0.045). Conclusions Candida auris BSI is not associated with an increased risk of mortality compared to BSI caused by other Candida spp. A higher risk for microbiologic recurrence occurred in the C. auris group.